Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy; Centre for Environmental, Nutritional and Genetic Epidemiology (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Diabetes Res Clin Pract. 2022 Sep;191:110051. doi: 10.1016/j.diabres.2022.110051. Epub 2022 Aug 27.
To assess if patients with type 2 diabetes mellitus (DM2) are: a) at excess risk of undergoing testing, contracting, and dying from SARS-CoV-2 infection compared to the general population; b) whether cardiovascular diseases (CAVDs) contribute to COVID-19-related death; and c) what is the effect of DM2 duration and control on COVID-19-related death.
This population-based study involved all 449,440 adult residents of the Reggio Emilia province, Italy. DM2 patients were divided in groups by COVID testing, presence of CAVDs and COVID death. Several mediation analyses were performed.
Patients with DM2 had an increased likelihood of being tested (Odds ratio, OR 1.27 95 %CI 1.23-1.30), testing positive (OR 1.21 95 %CI 1.16-1.26) and dying from COVID-19 (OR 1.75 95 %CI 1.54-2.00). COVID-19-related death was almost three times higher among obese vs non-obese patients with DM2 (OR 4.3 vs 1.6, respectively). For COVID-19 death, CAVDs mediated a) just 5.1 % of the total effect of DM2, b) 40 % of the effect of DM2 duration, and c) did not mediate the effect of glycemic control.
For COVID-19-related deaths in DM2 patients, the effect is mostly direct, obesity amplifies it, DM2 control and duration are important predictors, while CAVDs only slightly mediates it.
评估 2 型糖尿病(DM2)患者与普通人群相比:a)是否面临更高的 SARS-CoV-2 感染检测、感染和死亡风险;b)心血管疾病(CAVDs)是否导致与 COVID-19 相关的死亡;c)DM2 病程和控制情况对与 COVID-19 相关的死亡的影响。
本研究基于人群,纳入了意大利雷焦艾米利亚省的所有 449440 名成年居民。DM2 患者根据 COVID 检测、CAVDs 存在和 COVID 死亡情况分组。进行了多项中介分析。
DM2 患者更有可能接受检测(优势比,OR 1.27,95%可信区间,CI 1.23-1.30)、检测阳性(OR 1.21,95%CI 1.16-1.26)和死于 COVID-19(OR 1.75,95%CI 1.54-2.00)。与非肥胖 DM2 患者相比,肥胖 DM2 患者的 COVID-19 相关死亡风险几乎高出三倍(OR 4.3 比 1.6)。对于 COVID-19 死亡,CAVDs 介导了 a)DM2 总效应的 5.1%,b)DM2 病程效应的 40%,c)不介导血糖控制的效应。
对于 DM2 患者的 COVID-19 相关死亡,其效应主要是直接的,肥胖会放大其效应,DM2 控制和病程是重要的预测因素,而 CAVDs 仅轻微介导其效应。